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Introduction
Transarterial chemoembolization (TACE) is the current
standard of care in patients with hepatocellular carcinoma
(HCC) when curative therapies, including hepatic resec-
tion, image-guided ablation, or liver transplantation, are
precluded. In the multicenter PRECISION V study com-
paring conventional lipiodol-based TACE with drug-elut-
ing bead TACE (DEB-TACE) in patients with
intermediate-stage HCC, DEB-TACE was associated with
lesser cardiac and hepatic toxicity although no superior
survival benefit was confirmed [1]. In choosing the optimal
size of DEB, the use of 100–300-lm DEB is generally
recommended since this is the most commonly available
size, but there is still relatively lack of comparative data on
the optimal size of the beads. Recently, drug-eluting beads
with a diameter of 40 ± 10 lm have been introduced.
Theoretically, smaller beads penetrate deeper within a
tumor allowing more effective drug delivery. We report a
case of TACE with 40-lm beads in a patient with hepa-
tocellular carcinoma with histopathological correlation.
Case Report
Medical ethical approval is not required in our institution
for anonymized case reports. Informed consent was
obtained for the procedure. A 57-year-old woman with
hepatitis C cirrhosis and Child-Pugh classification C
underwent 3-phase contrast-enhanced computed tomogra-
phy (CECT) as part of screening for liver transplantation. A
solitary, 2.5-cm exophytic lesion was seen in segment 8
(Fig. 1A, B). The lesion showed marked enhancement in
the arterial phase and wash-out in the delayed venous
phase, and the diagnosis of HCC was made. Blood tests
showed the following results: bilirubin 75 l/L (reference
range 5–21 l/L), albumin 28 g/L (reference range
37–47 g/L), ASAT 80 U/L (reference range 12–37 U/L),
alkaline phosphatase 172 U/L (reference range 30–120
U/L), thrombocytes 64 9 109/L (reference range
145–370 9 109/L), and INR 1.5 (reference range 0.8–1.2).
Radio-frequency ablation (RFA) was considered as a
‘‘bridge-to-transplant’’, but the risk of RFA was considered
to be high because of (1) the subcapsular location, (2)
location in the dome of the liver, (3) Chilaiditi’s sign, and
(4) deranged coagulation profile. TACE with 40-lm drug-
eluting beads was therefore performed as the bridging
therapy (Fig. 1C, D). Catheterization was performed via a
femoral artery, and superselective embolization of sub-
segmental arteries of segment 8 was performed using a
2.4F Progreat microcatheter (Terumo, Tokyo, Japan).
Cone-beam computed tomography (CBCT) was performed
to ensure that the tumor was targeted accurately and
completely. One and a half milliliters of DEB 40 ± 10 lm
(Tandem; CeloNova BioSciences, Newnan, GA) loaded
with 50 mg of doxorubicin was injected until stasis was
observed in the tumor-feeding arteries. Unenhanced CBCT
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was repeated immediately after the procedure and
demonstrated satisfactory staining (Fig. 2A). Follow-up
CECT 6 weeks later demonstrated reduction in tumor size
to 1.3 cm and absence of enhancement (Fig. 2B), consis-
tent with complete response according to modified
response evaluation criteria in solid tumors (mRECIST)
criteria. The patient underwent liver transplantation
5 months later. Histopathology of the liver specimen
demonstrated complete necrosis of the tumor with a high
number of DEB within the tumor and penetration of beads
as far as into the interstitium (Fig. 3).
Discussion
Over the past decade,DEB-TACEhas replaced conventional
TACE in many, mostly European, centers. Most centers in
Asia, where HCCs are prevalent, still use conventional
TACE. The advantage of DEB-TACE is that it allows stan-
dardization of the chemotherapeutic dose with sustained,
slow drug release. Yet, beads of 100–300 or 300–500 lm do
not penetrate deep into the vascular bed. An animal study has
demonstrated that beads of 100–300 lm size predominantly
lodge in periphery of tumors with limited penetration to the
central part of the lesion and that beads of 300–500 lm
usually do not even reach the tumor [2]. The advantage of
conventional TACE is that it allows deep, large volume
penetrations of lipiodol emulsions. A previous animal study
has concluded that the optimal formula of water-in-oil
emulsion with a droplet diameter of 30–120 lm allows most
hepatic tumor uptake with limited pulmonary uptake [3].
In a recent animal study, histological examinations
showed that 40-lm Tandem microspheres do penetrate
deep into the tumor [4]. Our case confirms that 40-lm
Tandem beads allow deep and large volume implantation
into the tumor. Histological examinations showed the




the segment 8 of the liver with
Chilaiditi’s sign. B Axial image
of the delayed-phase contrast
CT showed the segment 8 tumor
had contrast wash-out.
C Hepatic digital subtraction
angiography before TACE
showed fine tumor stains with
small feeding subsegmental




enhancement within the tumor
Fig. 2 A Superselective TACE
was performed. Cone-beam CT
immediately after TACE
showed satisfactory staining of
the tumor. B Follow-up CT
showed devascularization and
shrinkage of the tumor
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presence of doxorubicin beads within the interstitium of the
tumor, the deepest level achievable. The number of beads
within the tumor was remarkably high, which is probably
accounted for by the fact that the 40-lm TANDEM
microspheres have 21 9 108 microspheres per mL, 210
times the conventional 100–300-lm DEB.
A study by Kwan et al. demonstrated that the level of
vascular occlusion and necrosis correlates with vessel size,
with the odds of achieving complete necrosis for a feeding
artery larger than 0.9 mm which is approximately 3–5
times higher than with a feeding artery\0.9 mm in size
[5]. Nonetheless, tumors may have a large degree of vari-
ation in vessel diameter, and hence perfect matching is
often not feasible. We reserved the use of 40-lm Tandem
microspheres in those HCC cases where the feeding hep-
atic artery vessel is\1 mm in size anticipating for those
cases when early stasis would be encountered with larger
beads. With the smaller particle size comparable to droplet
size of drug–oil emulsion, 40-lm Tandem beads may allow
drug delivery deep into the tumor comparable to conven-
tional TACE. At the same time, it offers the advantages of
drug-eluting beads.
No pulmonary or biliary complications occurred in our
case. Potentially, TACE with smaller-sized embolic agents
can result in biliary damage and liver dysfunction [6]. It is
pertinent to be aware of arteriohepatovenous shunting to
avoid pulmonary damage. In cases where significant arte-
riovenous shunting is seen or suspected, embolization with
40-lm beads would probably be contra-indicated.
Nonetheless, we should be aware of the potential pul-
monary uptake through radiologically occult transtumoral
arteriovenous shunts when we use smaller-sized DEB.
In conclusion, our report demonstrates that 40-lm drug-
eluting beads may reach deep into a hepatocellular carci-
noma and in large quantities. Careful case selection and
further studies are needed to validate the use of these small-
sized particles in the treatment of HCC.
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Fig. 3 Histopathology images of the explanted liver. A Necrotic
hepatic tumor (black asterisk), surrounded by DEB (white arrows)
and marked extravasation of inflammatory cells (black arrows).
Adjacent cirrhotic nodule was present (white asterisk) (hematoxylin
and eosin stain; original magnification, 910). B Necrotic tumor
(black asterisk) with DEB present within (black arrows) and
surrounding the tumor (white arrows) (hematoxylin and eosin stain;
original magnification, 95). C DEB (white arrows) surrounded by
multinucleated giant cells of foreign body type (hematoxylin and
eosin stain; original magnification, 940). D DEB (white arrows), in
large numbers, within the interstitium, with adjacent capillaries
observed. (CD34 immunostaining of capillaries; original magnifica-
tion, 920)
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